Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy
of Saroglitazar Magnesium 2 mg and 4 mg in patients with NASH. This study will be initiated
after obtaining the approvals of Institutional Ethics Committee/Institutional Review Board
(IEC/IRB) and the local regulatory authority.